Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Head and Neck Cancer

  Free Subscription


07.05.2018

1 Anticancer Res
1 BMC Cancer
1 Clin Cancer Res
2 Clin Nucl Med
2 Gastrointest Endosc
1 Head Neck
1 Int J Cancer
1 J Clin Endocrinol Metab
2 J Laryngol Otol
6 Oral Oncol
1 Otolaryngol Head Neck Surg
2 Radiother Oncol
7 Thyroid


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Anticancer Res

  1. CHOI SH, Chang JS, Choi J, Park SH, et al
    Re-irradiation Using Intensity-modulated Radiotherapy for Recurrent and Second Primary Head and Neck Cancer.
    Anticancer Res. 2018;38:3165-3173.
    PubMed     Text format     Abstract available


    BMC Cancer

  2. PENHA RCC, Buexm LA, Rodrigues FR, de Castro TP, et al
    NKX2.5 is expressed in papillary thyroid carcinomas and regulates differentiation in thyroid cells.
    BMC Cancer. 2018;18:498.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  3. LIU Z, McMichael EL, Shayan G, Li J, et al
    Novel effector phenotype of Tim-3+ regulatory T cells leads to enhanced suppressive function in head and neck cancer patients.
    Clin Cancer Res. 2018 Apr 30. pii: 1078-0432.CCR-17-1350.
    PubMed     Text format     Abstract available


    Clin Nucl Med

  4. MAHAJAN S, Dunphy MP, Haque S, Pandit-Taskar N, et al
    Solitary Orbital Metastasis in Carcinoma Esophagus: Findings on Serial 18F-FDG PET/CT Scans.
    Clin Nucl Med. 2017 Nov 11. doi: 10.1097/RLU.0000000000001892.
    PubMed     Text format     Abstract available

  5. KOU Y, Shen G, Ou X, Huang R, et al
    Focal Pulmonary Uptake on 99mTc-Sestamibi Parathyroid Scintigraphy Due to Iatrogenic Microembolism.
    Clin Nucl Med. 2018;43:33-35.
    PubMed     Text format     Abstract available


    Gastrointest Endosc

  6. CODIPILLY DC, Qin Y, Dawsey SM, Kisiel J, et al
    Screening for esophageal squamous cell carcinoma: recent advances.
    Gastrointest Endosc. 2018 Apr 27. pii: S0016-5107(18)32662.
    PubMed     Text format    

  7. LIAO Z, Liao G, Yang X, Peng X, et al
    Transplantation of autologous esophageal mucosa to prevent stricture after circumferential endoscopic submucosal dissection of early esophageal cancer (with video).
    Gastrointest Endosc. 2018 Apr 25. pii: S0016-5107(18)32659.
    PubMed     Text format     Abstract available


    Head Neck

  8. NAIR D, Mair M, Singhvi H, Mishra A, et al
    Perineural invasion: Independent prognostic factor in oral cancer that warrants adjuvant treatment.
    Head Neck. 2018 Apr 29. doi: 10.1002/hed.25170.
    PubMed     Text format     Abstract available


    Int J Cancer

  9. YU C, Guo Y, Bian Z, Yang L, et al
    Association of low-activity ALDH2 and alcohol consumption with risk of esophageal cancer in Chinese adults: A population-based cohort study.
    Int J Cancer. 2018 Apr 29. doi: 10.1002/ijc.31566.
    PubMed     Text format     Abstract available


    J Clin Endocrinol Metab

  10. LABOURIER E
    Letter to the Editor: The Value of Molecular Testing for Effective Management of Patients With Indeterminate Thyroid Nodules.
    J Clin Endocrinol Metab. 2016;101:L76-7.
    PubMed     Text format    


    J Laryngol Otol

  11. FINGLAND P, Carswell V, Tikka T, Douglas CM, et al
    The value of chest X-ray in the Scottish Referral Guidelines for suspected head and neck cancer in 2144 patients.
    J Laryngol Otol. 2018 Apr 30:1-5. doi: 10.1017/S0022215118000282.
    PubMed     Text format     Abstract available

  12. CAKIR CETIN A, Dogan E, Ozay H, Kumus O, et al
    Submandibular gland invasion and feasibility of gland-sparing neck dissection in oral cavity carcinoma.
    J Laryngol Otol. 2018 May 3:1-6. doi: 10.1017/S0022215118000592.
    PubMed     Text format     Abstract available


    Oral Oncol

  13. LIN M, You R, Liu YP, Zhang YN, et al
    Beneficial effects of anti-EGFR agents, Cetuximab or Nimotuzumab, in combination with concurrent chemoradiotherapy in advanced nasopharyngeal carcinoma.
    Oral Oncol. 2018;80:1-8.
    PubMed     Text format     Abstract available

  14. HANEMAAIJER SH, van Gijn SE, Oosting SF, Plaat BEC, et al
    Data-Driven prioritisation of antibody-drug conjugate targets in head and neck squamous cell carcinoma.
    Oral Oncol. 2018;80:33-39.
    PubMed     Text format     Abstract available

  15. NULTON TJ, Kim NK, DiNardo LJ, Morgan IM, et al
    Patients with integrated HPV16 in head and neck cancer show poor survival.
    Oral Oncol. 2018;80:52-55.
    PubMed     Text format     Abstract available

  16. IOCCA O, Farcomeni A, Di Rocco A, Di Maio P, et al
    Locally advanced squamous cell carcinoma of the head and neck: A systematic review and Bayesian network meta-analysis of the currently available treatment options.
    Oral Oncol. 2018;80:40-51.
    PubMed     Text format     Abstract available

  17. CARPENTER DJ, Mowery YM, Broadwater G, Rodrigues A, et al
    The risk of carotid stenosis in head and neck cancer patients after radiation therapy.
    Oral Oncol. 2018;80:9-15.
    PubMed     Text format     Abstract available

  18. BASHEER HA, Pakanavicius E, Cooper PA, Shnyder SD, et al
    Hypoxia modulates CCR7 expression in head and neck cancers.
    Oral Oncol. 2018;80:64-73.
    PubMed     Text format     Abstract available


    Otolaryngol Head Neck Surg

  19. KRAVIETZ A, Angara P, Le M, Sargi Z, et al
    Disparities in Screening for Head and Neck Cancer: Evidence from the NHANES, 2011-2014.
    Otolaryngol Head Neck Surg. 2018 Apr 1:194599818773074.
    PubMed     Text format     Abstract available


    Radiother Oncol

  20. GREGOIRE V, Grau C
    In reply to "A Long-Awaited Guideline for the Delineation of Primary Tumor in Head and Neck Cancer, and a Few Concerns about It" by Sezin Yuce Sari et al.
    Radiother Oncol. 2018 Apr 27. pii: S0167-8140(18)30175.
    PubMed     Text format    

  21. YUCE SARI S, Yeginer M, Cengiz M
    A long-awaited guideline for the delineation of primary tumor in head and neck cancer, and a few concerns about it.
    Radiother Oncol. 2018 Apr 24. pii: S0167-8140(18)30177.
    PubMed     Text format    


    Thyroid

  22. WILSON L, Huang W, Chen L, Ting J, et al
    Cost-Effectiveness of Lenvatinib, Sorafenib, and Placebo in the Treatment of Radioiodine Refractory Differentiated Thyroid Cancer.
    Thyroid. 2017 May 9. doi: 10.1089/thy.2016.0572.
    PubMed     Text format     Abstract available

  23. POLE JD, Zuk AM, Wasserman JD
    Diagnostic and Treatment Patterns among Children, Adolescents and Young Adults with Thyroid Cancer in Ontario: 1992-2010.
    Thyroid. 2017 May 17. doi: 10.1089/thy.2016.0629.
    PubMed     Text format     Abstract available

  24. GONZALEZ HE, Martinez JR, Vargas S, Solar A, et al
    A 10-gene classifier for indeterminate thyroid nodules: Development and multicenter accuracy study.
    Thyroid. 2017 May 18. doi: 10.1089/thy.2017.0067.
    PubMed     Text format     Abstract available

  25. PILLI T, Cantara S, Marzocchi C, Cardinale S, et al
    Diagnostic Value of Circulating microRNA-95 and -190 in the Differential Diagnosis of Thyroid Nodules: A Validation Study in 1000 Consecutive Patients.
    Thyroid. 2017 Jun 12. doi: 10.1089/thy.2017.0035.
    PubMed     Text format     Abstract available

  26. SILVA-VIEIRA M, Carrilho-Vaz S, Esteves S, C Ferreira T, et al
    Second Primary Cancer in Patients with Differentiated Thyroid Cancer: Does Radioiodine Play a Role?
    Thyroid. 2017 Jun 14. doi: 10.1089/thy.2016.0655.
    PubMed     Text format     Abstract available

  27. TANG AL, Falciglia M, Yang H, Mark JR, et al
    Validation of ATA Ultrasound Risk Assessment of Thyroid Nodules Selected for Ultrasound Fine Needle Aspiration.
    Thyroid. 2017 Jun 28. doi: 10.1089/thy.2016.0555.
    PubMed     Text format     Abstract available

  28. KLUBO-GWIEZDZINSKA J, Yang LA, Merkel R, Patel D, et al
    Results of screening in familial nonmedullary thyroid cancer.
    Thyroid. 2017 Jun 28. doi: 10.1089/thy.2016.0668.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Head and Neck Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: